NEW YORK – Flagship Pioneering said Wednesday that it has expanded an existing strategic partnership with Pfizer to include two new research programs that will be led by Quotient Therapeutics and Pioneering Medicines, Flagship's drug development unit.
Under the collaboration, the companies will analyze somatic mutations in patient tissue samples to inform the discovery and development of new therapies for cardiovascular and renal diseases.
According to Flagship, the Quotient agreement is its newest publicly announced program under the strategic partnership it inked with Pfizer in 2023.
"These two research programs will deploy our unique platform capabilities to identify novel links between genes and cardiovascular or renal disease, which are leading causes of mortality and morbidity around the world," said Quotient CEO and Cofounder Jacob Rubens.
Quotient's Somatic Genomics platform involves genome sequencing to identify disease-associated changes in isolated populations of suspicious cells. The company was founded by Flagship Pioneering in 2022.